Urocortins improve dystrophic skeletal muscle structure and function through both PKA- and Epac-dependent pathways.
about
Alterations of cAMP-dependent signaling in dystrophic skeletal muscleIsobaric Tagging-Based Quantification for Proteomic Analysis: A Comparative Study of Spared and Affected Muscles from mdx Mice at the Early Phase of DystrophyUrocortin-1 Mediated Cardioprotection Involves XIAP and CD40-Ligand Recovery: Role of EPAC2 and ERK1/2Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel TherapiesUrocortin 3 activates AMPK and AKT pathways and enhances glucose disposal in rat skeletal muscle.Participation of myosin Va and Pka type I in the regeneration of neuromuscular junctions.Diapocynin, a dimer of the NADPH oxidase inhibitor apocynin, reduces ROS production and prevents force loss in eccentrically contracting dystrophic muscleCaloric restriction induces energy-sparing alterations in skeletal muscle contraction, fiber composition and local thyroid hormone metabolism that persist during catch-up fat upon refeeding.cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regenerationInhibition of iPLA2 β and of stretch-activated channels by doxorubicin alters dystrophic muscle function.Restoration of pharyngeal dilator muscle force in dystrophin-deficient (mdx) mice following co-treatment with neutralizing interleukin-6 receptor antibodies and urocortin 2.In vivo neutralization of IL-6 receptors ameliorates gastrointestinal dysfunction in dystrophin-deficient mdx mice.Combined XIL-6R and urocortin-2 treatment restores MDX diaphragm muscle force.Urocortin-2 Prevents Dysregulation of Ca2+ Homeostasis and Improves Early Cardiac Remodeling After Ischemia and Reperfusion.Dystrophin Cardiomyopathies: Clinical Management, Molecular Pathogenesis and Evolution towards Precision MedicineTamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy
P2860
Q27003221-40E7E407-2648-4960-B0E3-348AE9E78D07Q28534074-A33108E8-8095-4FC6-AC9E-98E1A492F669Q28580796-E6395C74-0DFA-4EF9-9A7A-B348C3B147EDQ33608478-3C29E885-9C06-4670-BB85-671F94489210Q34312180-B3AAA6C0-9EBE-47AA-B25D-155C25C303AAQ34345318-76D40E2D-71E0-4D93-820A-875AC56519BBQ34444163-F82F5321-320C-4128-A8D4-825BA51218C6Q36097430-C2BC4927-940A-41CE-A08F-47C176E212A3Q36114861-B7A38410-9F9F-4EAE-AF50-8AA2DF7E5195Q37046769-EA730001-4002-4E9E-B6D4-7D35B6540263Q38700281-AF124B76-97E1-4541-BF2B-32F0BB9D114FQ43345556-62BA2F9B-095E-40A9-8493-D6925CB32C6BQ47949346-5E177402-5777-4A16-A204-A1278BCC6177Q55717210-D7AFF94A-6D97-4669-ABD6-BE2C297217FDQ58716650-E9A1A76A-9B8D-4AD2-83A0-739FF2B11B91Q59125219-152D3A5C-47AE-4FDB-A4E1-2251888E4D72
P2860
Urocortins improve dystrophic skeletal muscle structure and function through both PKA- and Epac-dependent pathways.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Urocortins improve dystrophic ...... - and Epac-dependent pathways.
@en
Urocortins improve dystrophic ...... - and Epac-dependent pathways.
@nl
type
label
Urocortins improve dystrophic ...... - and Epac-dependent pathways.
@en
Urocortins improve dystrophic ...... - and Epac-dependent pathways.
@nl
prefLabel
Urocortins improve dystrophic ...... - and Epac-dependent pathways.
@en
Urocortins improve dystrophic ...... - and Epac-dependent pathways.
@nl
P2093
P1476
Urocortins improve dystrophic ...... - and Epac-dependent pathways.
@en
P2093
François-Xavier Boittin
Julie Reutenauer-Patte
Olivier M Dorchies
Ophélie Patthey-Vuadens
P304
P356
10.1016/J.AJPATH.2011.10.038
P407
P50
P577
2011-12-19T00:00:00Z